TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Topical Capsaicin Cream for Stable Angina

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> or = 3 month history of chronic, stable, angina triggered by physical effort or mental/emotional stress~* documented stress-induced ST depression, reversible perfusion imaging, or wall motion abnormality or CAD \>50%~* Canadian Cardiovascular (CV) Class I-III~* Receiving medical therapy for \> or = 2 months~* Ability to perform Bruce Protocol treadmill test~* non-pregnant female~Exclusion Criteria:~* unstable angina~* revasc within 2 months~* Myocardial infarction (MI) within 2 months~* congestive heart failure (CHF) hospitalization within 2 months~* New York Heart Association (NYHA) class III or IV~* left ventricular ejection fraction (LVEF) \< 25%~* abnormal ECG; Acute changes on ECG~* Currently receiving treatment with investigational drugs/devices~* Uncontrolled hypertension~* contraindication to exercise stress testing~* allergy to red peppers or capsaicin~* skin deformity, scar, or rash at application site~* abdominal surgery within 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 0.1% Capsaicin Cream (Type: ACTIVE_COMPARATOR): 0.1% capsaicin cream spread 8cm x 15cm on abdomen, once, 45 minutes prior to exercise
- Placebo Cream (Type: PLACEBO_COMPARATOR): Inactive cream, 4cm spread 8cm x 15cm on the abdomen, once, 45 minutes prior to exercise

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TESS Shoulder Arthroplasty Data Collection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A pre-operative level of pain and function the same as for conventional joint replacement~* A likelihood of obtaining relief of pain and improved function~* Full skeletal maturity~* Ability to follow instructions~* Good general health for age~* Willing to return for follow-up evaluations~Exclusion Criteria:~* Glenohumeral joint infection, osteomyelitis~* Neuro-muscular complications~* Inability to co-operate with and complete the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TESS prosthesis (Type: None): Consecutive series of patients with a TESS prosthesis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ≥18 years of age with confirmed COVID-19 infection~* Patient must be able to complete consent and hold mask~* Baseline room air oxygen saturation \<94% or new supplemental oxygen requirement at presentation or patient on supplemental oxygen at baseline and requiring up-titration of oxygen setting~* Patient in negative pressure room~* Patient must have access to an internet-connected device~Exclusion Criteria:~* Tracheostomy~* History of pneumothorax or known bullous lung disease~* Recent cataract surgery~* Patient receiving NIV (Noninvasive Ventilation) or HFNC (High Flow Nasal Cannula)~* Patient receiving mechanical ventilation~* Delirium

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Device intervention (Type: ACTIVE_COMPARATOR): Intervention participants will receive the AirFLO2 device and training via video with reinforcement from the coordinator how to use and to self-apply it. Clinical data will be recorded before and after intervention. Questionnaires will be completed at baseline and at serial time points after intervention starts.
- Standard of Care- Control (Type: NO_INTERVENTION): Participants will receive standard of care, clinical data will be recorded. Baseline and end of study questionnaires will be performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impaired Gustatory Sensory Perception in Obese and Obese Diabetic Persons

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have provided written consent~* Patients over 18 years old~* Body Mass Index (BMI) \<25 kg/m² for healthy volunteers and BMI≥30 kg/m² for obese subjects~* Patients with type 2 diabetes for the group obese diabetic subjects~Exclusion Criteria:~* Patients under guardianship~* Patients without health insurance cover~* Pregnant or breast-feeding women~* Active smokers~* Subjects with type 2 diabetes for the  healthy subjects  and  obese subjects , subjects with type 1 diabetes for all groups~* Subjects who do not speak French~* Treatment that interferes with taste or acts on the central nervous system~* Anti-diabetic treatment with GLP-1 analogues (Glucagon-like peptide 1) or SGLT2 (sodium-glucose cotransporter type 2)~* Known hypersensitivity to the foods proposed in the study, or the paste used to fix the electrodes, or to paraffin wax or to the products tested (sucrose, glucose or starch for the gustatory evoked potentials and triangular tests)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- healthy subjects (Type: ACTIVE_COMPARATOR): None
- obese (Type: EXPERIMENTAL): None
- obese diabetic (Type: EXPERIMENTAL): None
- obese diabetic who are going to be operated on (Type: EXPERIMENTAL): 25 of a sleeve gastrectomy and 25 of a Y gastric bypass

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male subjects aged 18 and older.~2. Male subjects with at least 3 months of symptoms of CP/CPPS who are refractory to other therapies~3. Subjects with a minimum score of 15 on the CPSI.~4. Male subjects must give written informed consent.~5. Male subjects must be willing an able to comply with the most recent version of the FDA-mandated S.T.E.P.S.â Program to include:~   * He understands and can reliably carry out all instructions.~  * He is capable of complying with the mandatory contraceptive measures that are appropriate for male patient registration, and patient surveys as described in the S.T.E.P.S.â program.~  * He has received both oral and written warning of the hazards of taking thalidomide and exposing a fetus to the drug~  * He has received both oral and written warning of the risk of possible contraception failure and of the presence of thalidomide in semen. He has been instructed that he must always use a late condom during any sexual contact with a woman of childbearing potential, even if he has undergone a successful vasectomy.~  * He acknowledges in writing his understanding of these warning and of the need to use a latex condom during any sexual contact with women of childbearing potential, even if he has undergone a successful vasectomy.~  * He agrees NOT to be a sperm or blood donor while being treated with thalidomide -~Exclusion Criteria:~1. Subjects who are female.~2. Subjects with a documented positive urine culture (\>100,000 CFU/mL) within the past six months~3. Subjects with duration of symptoms less than three months~4. Subjects with active genital infections~5. Subjects with prior urologic surgeries~6. Subjects with known active or prior genitourinary cancers including renal, ureteral, bladder or prostate~7. Subjects having received prior radiation to the abdominal or pelvic area~8. Subjects with known bladder or ureteral calculi~9. Subjects unable to complete a voiding diary~10. Subjects diagnosed with neuropathy~11. Subjects with neutropenia~12. Subjects with a history of deep venous thrombosis, pulmonary embolism, or hypercoagulable state~13. Any patient who is not willing to comply with the most recent version of the FDA-mandated S.T.E.P.Sâ program~14. Subjects with orthostatic hypotension~15. Subjects with known malignancies in the last 2 years.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Thalidomide (Type: ACTIVE_COMPARATOR): Open Label drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Timing of B and O Suppositories to Help Relieve Post-operative Bladder Spasms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing lithotripsy procedure at GW Hospital~Exclusion Criteria:~* The criteria for exclusion for those patients who agree to participate in the study will be patients with glaucoma, severe hepatic or renal disease, bronchial asthma, respiratory depression at the time of administration, convulsive disorders, allergy to anti-muscarinics or opiates, history of anorectal surgery, pre-operative use of antimuscarinics, chronic pain, chronic use of analgesics, or a history of alcohol or opioid dependency.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Pre-operative Suppository (Type: EXPERIMENTAL): A B\&O Suppository will be placed in the patient's rectum after the induction of anesthesia, but before the surgery.
- Post-operative Suppository (Type: ACTIVE_COMPARATOR): A B\&O Suppository will be placed in the patient's rectum while still under anesthesia, but after the surgery.
- Rectal Exam (Type: PLACEBO_COMPARATOR): Patient's will be given a rectal exam after the procedure but while still under anesthesia to serve as a placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Is Doppler Necessary in Haemorrhoidal Artery Ligation Operation?

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* For consenting adults (18-90 years) with grade one and two piles listed for HALO at Poole hospital by three consultants trained in the HALO technique, the patients will be offered to be involved in the study.~Exclusion Criteria:~* Other grades of piles, age outside 18-90 or other anal condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Doppler (Type: None): Those patients where the doppler was randomised to be on
- Non doppler patients (Type: None): those with no doppler guidance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Liver cirrhosis~* ACLF grade 1, 2 or 3 (Canonic criteria)~* Signed informed consent~Exclusion Criteria:~* Acute or subacute liver failure without cirrhosis~* ACLF grade 1 with response to medical therapy~* Evidence of current malignancy including hepatocellular carcinoma (any grade) or alphafetoprotein \> 400 ng/ml~* Previous personal history of malignancy (active or in complete remission) or familiar history of hereditary cancer.~* Moderate or severe chronic heart failure (NYHA III-IV)~* Renal replacement therapy~* Severe chronic pulmonary disease (GOLD III-IV)~* Gastrointestinal bleeding in the last 5 days~* Previous liver transplantation~* Immunosuppressive therapy~* Extrahepatic cholestasis~* HIV infection~* Pregnant of breastfeeding women~* Pre-menopausal women who are of child bearing potential and are not practicing an acceptable method of birth control.~* Participation in any investigational trial in the last 3 months~* Active addition to illegal drugs~* Refusal to participate~* Patients who can not provide prior informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Allogenic Mesenchymal stem cells (Type: EXPERIMENTAL): Intravenous allogenic bone marrow derived mesenchymal stem cells: 4 doses of 2 x 106/kg administered on days 1, 4, 11 and 18
- Placebo (Type: PLACEBO_COMPARATOR): Solution without cells on days 1, 4, 11 and 18

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Successfully completed Study ICA-17043-10~* Discontinued Study 10 or 12 following the DMC recommendations because he/she was not on HU, and has since been on a stable dose of HU for at least 3 months prior to Day 1~* Male, or female not capable of becoming pregnant or using appropriate birth control~* Has willingly given written informed consent to participate in this study~Exclusion Criteria:~* The subject, if female, has a positive urine pregnancy test on Day 1 (before entering study)~* The subject is presently unsuitable for participation in this long-term study

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 66 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histological confirmation of adenocarcinoma of the colon or rectum that is metastatic and/ or unresectable~* Progression, intolerance, or contraindication to a fluoropyrimidine (e.g., 5- fluorouracil or capecitabine), oxaliplatin, irinotecan, an anti-VEGF monoclonal antibody (bevacizumab, ziv-aflibercept, or ramucirumab), and an anti-PD-1 monoclonal antibody (nivolumab or pembrolizumab) if tumor has deficient mismatch repair proteins (dMMR) or is microsatellite instability-high (MSI-H)~* For patients with KRAS and NRAS wild-type tumors, progression, intolerance, or contraindication to an anti-EGFR monoclonal antibody (cetuximab or panitumumab)~  * Note: If tissue is known to be positive for HER2 expression (IHC 3+) or the tumor has ERBB2 (HER2) amplification detected by a Clinical Laboratory Improvement Act (CLIA)-certified assay, prior treatment with anti-EGFR therapy is not required~* At least one site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version 1.1) that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation~* Life expectancy \>= 3 months per estimation of investigator~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2~* Capable of understanding and complying with the protocol requirements and has signed the informed consent document~* Satisfy at least one of the following two conditions:~  * Willing and able to provide blood sample for screening purposes~ * Guardant 360 testing completed =\< 60 days prior to registration~Exclusion Criteria:~* Evidence within the last 3 years of another malignancy which required systemic treatment. EXCEPTIONS: Non-melanotic skin cancer, carcinoma-in-situ of the cervix, or localized prostate cancer with a current PSA of \< 1.0mg/dL on 2 successive evaluations, at least 90 days apart, with the most recent evaluation no more than 4 weeks prior to registration~* Unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee~* History of solid organ transplantation~* Pregnant or planning to become pregnant within the next 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Screening (genetic testing) (Type: None): Patients submit blood samples for genetic testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Antibiotics After Hospital Discharge in Septic Abortion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted at the hospital with a diagnosis of infected abortion and about to be discharged from the hospital.~* Use of intravenous antibiotics (gentamicin and clindamycin)~* Improvement of the clinical conditions for at least 48 hours (no fever, eating and walking normally, reduced vaginal bleeding)~Exclusion Criteria:~* Unwilling to participate in the study.~* Use of antibiotics previously within one week.~* Presence of tubo-ovarian abscess.~* Known allergy to doxycycline or metronidazole.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Patients that receive up to 10 days of doxycycline 200mg/day and metronidazole 500mg/day
- 2 (Type: PLACEBO_COMPARATOR): Patients that do not receive antibiotics, only placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Upper Extremity Rehabilitation Using Smart Glove in Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CT or MRI proved 1st stroke patients with unilateral hemiplegia caused by stroke (ischemic, hemorrhagic, intracranial hemorrhage)~* 72 hours \~ 3 months after stroke~* Upper extremity hemiplegia with Brunnström stage 2-5.~* The patients can sit to receive treatment for at least 1 hour~Exclusion Criteria:~* The patients cannot perform occupational treatments because of severe hemineglect or hemianopia~* Contracture due to severe limitation of motion~* Upper extremity spasticity in the wrist and fingers with modified Ashworth scale \> 2 points~* Fugl-Meyer Assessment-Wrist \& Hand score \>= 21 points~* moderate to severe cognitive dysfunction \< MMSE 18 points~* Severe aphasia~* The patients who has been diagnosed as malignant tumor

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Smart Glove Group (Type: EXPERIMENTAL): The subjects will be treated with conventional occupational therapy for 30 minutes and smart glove treatment for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
- Homework group (Type: NO_INTERVENTION): The subjects will be treated with conventional occupational therapy for 30 minutes and upper extremity rehabilitation homework which means the self training at bedside, for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Active MOBility Early After Stroke : What Should be the Best Physiotherapy Early After Stroke ?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients informed and giving their written consent.First~* Ever ischemic hemispheric or haemorrhagic stroke, unilateral, occurred between the 25th and the 72nd previous hours~* Age ≥ 18 years old~* Motricity quoted by an NIHSS \>=2 in the upper limb or in the lower limb~Exclusion Criteria:~* Patient without health insurance.~* Coma (NIHSS consciousness \> or = 2)~* Total recovery within the 24 first hours~* Brain stem or cerebellar stroke~* Previous neurological history, specially stroke or dementia~* Inability to understand the study~* Surgical treatment of the stroke~* Autonomy before stroke assessed by Rankin score different from 0~* Scheduled surgery in the following 15 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- group 1: standard physiotherapy (Type: PLACEBO_COMPARATOR): daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day.
- group 2: experimental physiotherapy (Type: EXPERIMENTAL): physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues